Skip to main content
Search
Search
Quick Search anywhere
Quick Search in Journals
Quick Search in Journals
Quick Search in Journals
Quick Search in Journals
Quick Search in Journals
Quick Search in Journals
Quick Search in Journals
Quick Search in Journals
Quick Search in Journals
Quick Search in Journals
Skip main navigationClose Drawer MenuOpen Drawer Menu
JACC Journals › JACC › Archives › Vol. 81 No. 3
Previous
Next

Albuminuria and Heart Failure: JACC State-of-the-Art ReviewGET ACCESS

JACC State-of-the-Art Review

J Am Coll Cardiol. 2023 Jan, 81 (3) 270–282
Topic(s):
Sections

Central Illustration

Abstract

Although chronic kidney disease is characterized by low glomerular filtration rate (GFR) or albuminuria, estimated GFR (eGFR) is more widely utilized as a marker of risk profile in cardiovascular diseases, including heart failure (HF). The presence and magnitude of albuminuria confers a strong prognostic association in forecasting risk of incident HF as well as its progression, irrespective of eGFR. Despite the high prevalence of albuminuria in HF, whether it adds incremental prognostic information in clinical practice and serves as an independent risk marker, and whether there are any therapeutic implications of assessing albuminuria in patients with HF is less well-established. In this narrative review, we assess the potential role of albuminuria in risk profiling for development and progression of HF, strengths and limitations of utilizing albuminuria as a risk marker, its ability to serve in HF risk prediction models, and the implications of adopting albuminuria as an effective parameter in cardiovascular trials and practice.

Highlights

•

Albuminuria is prevalent in patients with heart failure and confers a strong, consistent and independent association with risk.

•

The causes of albuminuria in patients with heart failure are incompletely understood, as are the mechanisms linking it to disease progression and adverse outcomes.

•

Interventions that reduce albuminuria may potentially lower the risk of incident heart failure or prevent progression of existing heart failure.

References

  • 1. Ronco C., House A.A., Haapio M. "Cardiorenal and renocardiac syndromes: the need for a comprehensive classification and consensus". Nat Clin Pract Nephrol 2008;4:310-311.

    CrossrefMedlineGoogle Scholar

  • 2. Tonelli M., Wiebe N., Culleton B., et al. "Chronic kidney disease and mortality risk: a systematic review". J Am Soc Nephrol 2006;17:2034-2047.

    CrossrefMedlineGoogle Scholar

  • 3. Schrier R.W. "Role of diminished renal function in cardiovascular mortality: marker or pathogenetic factor?"J Am Coll Cardiol 2006;47:1-8.

    View ArticleGoogle Scholar

  • 4. Hillege H.L., Girbes A.R.J., De Kam P.J., et al. "Renal function, neurohormonal activation, and survival in patients with chronic heart failure". Circulation 2000;102:203-210.

    CrossrefMedlineGoogle Scholar

  • 5. Kidney Disease: Improving Global Outcomes. "CKD evaluation and management". https://kdigo.org/guidelines/ckd-evaluation-and-management/. Accessed March 14, 2021.

    Google Scholar

  • 6. Bakris G.L., Molitch M. "Microalbuminuria as a risk predictor in diabetes: the continuing saga". Diabetes Care 2014;37:867-875.

    CrossrefMedlineGoogle Scholar

  • 7. Ingelsson E., Sundström J., Lind L., et al. "Low-grade albuminuria and the incidence of heart failure in a community-based cohort of elderly men". Eur Heart J 2007;28:1739-1745.

    CrossrefMedlineGoogle Scholar

  • 8. Kottgen A., Russell S.D., Loehr L.R., et al. "Reduced kidney function as a risk factor for incident heart failure: the Atherosclerosis Risk in Communities (ARIC) study". J Am Soc Nephrol 2007;18:1307-1315.

    CrossrefMedlineGoogle Scholar

  • 9. Lam C.S.P., Lyass A., Kraigher-Krainer E., et al. "Cardiac dysfunction and noncardiac dysfunction as precursors of heart failure with reduced and preserved ejection fraction in the community". Circulation 2011;124:24-30.

    CrossrefMedlineGoogle Scholar

  • 10. Damman K., Valente M.A.E., Voors A.A., O’Connor C.M., van Veldhuisen D.J., Hillege H.L. "Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis". Eur Heart J 2014;35:455-469.

    CrossrefMedlineGoogle Scholar

  • 11. Jackson C.E., Solomon S.D., Gerstein H.C., et al. "Albuminuria in chronic heart failure: prevalence and prognostic importance". Lancet 2009;374:543-550.

    CrossrefMedlineGoogle Scholar

  • 12. Dries D.L., Exner D.V., Domanski M.J., Greenberg B., Stevenson L.W. "The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction". J Am Coll Cardiol 2000;35:681-689.

    View ArticleGoogle Scholar

  • 13. Weir M.R. "Microalbuminuria and cardiovascular disease". Clin J Am Soc Nephrol 2007;2:581-590.

    CrossrefMedlineGoogle Scholar

  • 14. Chugh A., Bakris G.L. "Microalbuminuria: what is it? Why is it important? What should be done about it? An update". J Clin Hypertens (Greenwich) 2007;9:196-200.

    CrossrefMedlineGoogle Scholar

  • 15. Deckert T., Feldt-Rasmussen B., Borch-Johnsen K., Jensen T., Kofoed-Enevoldsen A. "Albuminuria reflects widespread vascular damage—the Steno hypothesis". Diabetologia 1989;32:219-226.

    CrossrefMedlineGoogle Scholar

  • 16. Kriz W. "Ontogenetic development of the filtration barrier". Nephron Exp Nephrol 2007;106:e44-e50.

    CrossrefMedlineGoogle Scholar

  • 17. Benzing T., Salant D. "Insights into glomerular filtration and albuminuria". N Engl J Med 2021;384:1437-1446.

    CrossrefMedlineGoogle Scholar

  • 18. Erkan E., de Leon M., Devarajan P. "Albumin overload induces apoptosis in LLC-PK1 cells". Am J Physiol Renal Physiol 2001;280:

    CrossrefMedlineGoogle Scholar

  • 19. Abbate M., Zoja C., Remuzzi G. "How does proteinuria cause progressive renal damage?"J Am Soc Nephrol 2006;17:2974-2984.

    CrossrefMedlineGoogle Scholar

  • 20. Satchell S.C., Tooke J.E. "What is the mechanism of microalbuminuria in diabetes: a role for the glomerular endothelium?"Diabetologia 2008;51:714-725.

    CrossrefMedlineGoogle Scholar

  • 21. Seliger S.L., Salimi S., Pierre V., Giffuni J., Katzel L., Parsa A. "Microvascular endothelial dysfunction is associated with albuminuria and CKD in older adults". BMC Nephrol 2016;17:82.

    CrossrefMedlineGoogle Scholar

  • 22. de Zeeuw D., Parving H.H., Henning R.H. "Microalbuminuria as an early marker for cardiovascular disease". J Am Soc Nephrol 2006;17:2100-2105.

    CrossrefMedlineGoogle Scholar

  • 23. Moorhead J.F., El-Nahas M., Chan M.K., Varghese Z. "Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease". Lancet 1982;320:1309-1311.

    CrossrefGoogle Scholar

  • 24. Tonneijck L., Muskiet M.H.A., Smits M.M., et al. "Glomerular hyperfiltration in diabetes: mechanisms, clinical significance, and treatment". J Am Soc Nephrol 2017;28:1023-1039.

    CrossrefMedlineGoogle Scholar

  • 25. Williams M.E. "Diabetic nephropathy: the proteinuria hypothesis". Am J Nephrol 2005;25:77-94.

    CrossrefMedlineGoogle Scholar

  • 26. Cohen M.P., Chen S., Ziyadeh F.N., et al. "Evidence linking glycated albumin to altered glomerular nephrin and VEGF expression, proteinuria, and diabetic nephropathy". Kidney Int 2005;68:1554-1561.

    CrossrefMedlineGoogle Scholar

  • 27. Siddiqi F.S., Advani A. "Endothelial-podocyte crosstalk: the missing link between endothelial dysfunction and albuminuria in diabetes". Diabetes 2013;62:3647-3655.

    CrossrefMedlineGoogle Scholar

  • 28. Shah S.J., Borlaug B.A., Kitzman D.W., et al. "Research priorities for heart failure with preserved ejection fraction: National Heart, Lung, and Blood Institute working group summary". Circulation 2020;141:1001-1026.

    CrossrefMedlineGoogle Scholar

  • 29. Nayor M., Larson M.G., Wang N., et al. "The association of chronic kidney disease and microalbuminuria with heart failure with preserved vs reduced ejection fraction". Eur J Heart Fail 2017;19:615-623.

    CrossrefMedlineGoogle Scholar

  • 30. Damman K., van Deursen V.M., Navis G., Voors A.A., van Veldhuisen D.J., Hillege H.L. "Increased central venous pressure is associated with impaired renal function and mortality in a broad spectrum of patients with cardiovascular disease". J Am Coll Cardiol 2009;53:582-588.

    View ArticleGoogle Scholar

  • 31. Damman K., van Veldhuisen D.J., Navis G., Voors A.A., Hillege H.L. "Urinary neutrophil gelatinase associated lipocalin (NGAL), a marker of tubular damage, is increased in patients with chronic heart failure". Eur J Heart Fail 2008;10:997-1000.

    CrossrefMedlineGoogle Scholar

  • 32. National Kidney Foundation. "ACR". https://www.kidney.org/kidneydisease/siemens_hcp_acr. Accessed March 2, 2022.

    Google Scholar

  • 33. National Clinical Guideline Centre (UK). "Chronic kidney disease (partial update): early identification and management of chronic kidney disease in adults in primary and secondary care". London: National Institute for Health and Care Excellence (UK), 2014. https://pubmed.ncbi.nlm.nih.gov/25340245/. Accessed March 2, 2022.

    Google Scholar

  • 34. Ralston S.H., Caine N., Richards I., O’Reilly D., Sturrock R.D., Capell H.A. "Screening for proteinuria in a rheumatology clinic: comparison of dipstick testing, 24 hour urine quantitative protein, and protein/creatinine ratio in random urine samples". Ann Rheum Dis 1988;47:759-763.

    CrossrefMedlineGoogle Scholar

  • 35. Waikar S.S., Rebholz C.M., Zheng Z., et al. "Biological variability of estimated GFR and albuminuria in CKD". Am J Kidney Dis 2018;72:538-546.

    CrossrefMedlineGoogle Scholar

  • 36. Rocco M.V., Berns J.S. "KDOQI clinical practice guideline for diabetes and CKD: 2012 update". Am J Kidney Dis 2012;60:850-886.

    CrossrefMedlineGoogle Scholar

  • 37. Garg A.X., Kiberd B.A., Clark W.F., Haynes R.B., Clase C.M. "Albuminuria and renal insufficiency prevalence guides population screening: results from the NHANES III". Kidney Int 2002;61:2165-2175.

    CrossrefMedlineGoogle Scholar

  • 38. Zacharias J.M., Young T.K., Riediger N.D., Roulette J., Bruce S.G. "Prevalence, risk factors and awareness of albuminuria on a Canadian First Nation: a community-based screening study". BMC Public Health 2012;12:290.

    CrossrefMedlineGoogle Scholar

  • 39. Masson S., Latini R., Milani V., et al. "Prevalence and prognostic value of elevated urinary albumin excretion in patients with chronic heart failure data from the GISSI–Heart Failure trial". Circ Heart Fail 2010;3:65-72.

    CrossrefMedlineGoogle Scholar

  • 40. Orea-Tejeda A., Colín-Ramírez E., Hernández-Gilsoul T., et al. "Microalbuminuria in systolic and diastolic chronic heart failure patients". Cardiol J 2008;15:143-149.

    MedlineGoogle Scholar

  • 41. Katz D.H., Burns J.A., Aguilar F.G., Beussink L., Shah S.J. "Albuminuria is independently associated with cardiac remodeling, abnormal right and left ventricular function, and worse outcomes in heart failure with preserved ejection fraction". J Am Coll Cardiol HF 2014;2:586-596.

    Google Scholar

  • 42. Miura M., Shiba N., Nochioka K., et al. "Urinary albumin excretion in heart failure with preserved ejection fraction: an interim analysis of the CHART 2 study". Eur J Heart Fail 2012;14:367-376.

    CrossrefMedlineGoogle Scholar

  • 43. De Zeeuw D., Remuzzi G., Parving H.H., et al. "Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy". Circulation 2004;110:921-927.

    CrossrefMedlineGoogle Scholar

  • 44. Bahrami H., Bluemke D.A., Kronmal R., et al. "Novel metabolic risk factors for incident heart failure and their relationship with obesity. The MESA (Multi-Ethnic Study of Atherosclerosis) study". J Am Coll Cardiol 2008;51:1775-1783.

    View ArticleGoogle Scholar

  • 45. Blecker S., Matsushita K., Kttgen A., et al. "High-normal albuminuria and risk of heart failure in the community". Am J Kidney Dis 2011;58:47-55.

    CrossrefMedlineGoogle Scholar

  • 46. Gerstein H.C., Mann J.F.E., Yi Q., et al. "Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals". J Am Med Assoc 2001;286:421-426.

    CrossrefMedlineGoogle Scholar

  • 47. Ärnlöv J., Evans J.C., Meigs J.B., et al. "Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study". Circulation 2005;112:969-975.

    CrossrefMedlineGoogle Scholar

  • 48. Brouwers F.P., de Boer R.A., van der Harst P., et al. "Incidence and epidemiology of new onset heart failure with preserved vs reduced ejection fraction in a community-based cohort: 11-year follow-up of PREVEND". Eur Heart J 2013;34:1424-1431.

    CrossrefMedlineGoogle Scholar

  • 49. Pitt B., Filippatos G., Agarwal R., et al. "Cardiovascular events with finerenone in kidney disease and type 2 diabetes". N Engl J Med 2021;385:2252-2263.

    CrossrefMedlineGoogle Scholar

  • 50. Bakris G.L., Agarwal R., Anker S.D., et al. "Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes". N Engl J Med 2020;383:2219-2229.

    CrossrefMedlineGoogle Scholar

  • 51. Capes S.E., Gerstein H.C., Negassa A., Yusuf S. "Enalapril prevents clinical proteinuria in diabetic patients with low ejection fraction". Diabetes Care 2000;23:377-380.

    CrossrefMedlineGoogle Scholar

  • 52. Shuvy M., Zwas D.R., Lotan C., Keren A., Gotsman I. "Albuminuria: associated with heart failure severity and impaired clinical outcomes". Can J Cardiol 2020;36:527-534.

    CrossrefMedlineGoogle Scholar

  • 53. Selvaraj S., Claggett B., Shah S.J., et al. "Prognostic value of albuminuria and influence of spironolactone in heart failure with preserved ejection fraction". Circ Heart Fail 2018;11:e005288.

    CrossrefMedlineGoogle Scholar

  • 54. National Institute of Diabetes and Digestive and Kidney Diseases. "United States Renal Data System". https://www.usrds.org/annual-data-report/. Accessed August 31, 2022.

    Google Scholar

  • 55. Szczech L.A., Stewart R.C., Su H.L., et al. "Primary care detection of chronic kidney disease in adults with Type-2 diabetes: The ADD-CKD study (awareness, detection and drug therapy in type 2 diabetes and chronic kidney disease)". PLoS One 2014;9:e110535.

    CrossrefMedlineGoogle Scholar

  • 56. Atthobari J., Asselbergs F.W., Boersma C., et al. "Cost-effectiveness of screening for albuminuria with subsequent fosinopril treatment to prevent cardiovascular events: a pharmacoeconomic analysis linked to the Prevention of Renal and Vascular Endstage Disease (PREVEND) study and the Prevention of Renal and Vascular Endstage Disease Intervention Trial (PREVEND IT)". Clin Ther 2006;28:432-444.

    CrossrefMedlineGoogle Scholar

  • 57. Kessler R., Keusch G., Szucs T.D., et al. "Health economic modelling of the cost-effectiveness of microalbuminuria screening in Switzerland". Swiss Med Wkly 2012;142:w13508.

    Google Scholar

  • 58. Butler B., Kalogeropoulos A., Georgiopoulou V., et al. "Incident heart failure prediction in the elderly: the health ABC heart failure score". Circ Heart Fail 2008;1:125-133.

    CrossrefMedlineGoogle Scholar

  • 59. DeFilippi C.R., De Lemos J.A., Christenson R.H., et al. "Association of serial measures of cardiac troponin T using a sensitive assay with incident heart failure and cardiovascular mortality in older adults". JAMA 2010;304:2494-2502.

    CrossrefMedlineGoogle Scholar

  • 60. Velagaleti R.S., Gona P., Larson M.G., et al. "Multimarker approach for the prediction of heart failure incidence in the community". Circulation 2010;122:1700-1706.

    CrossrefMedlineGoogle Scholar

  • 61. Berg D.D., Wiviott S.D., Scirica B.M., et al. "Heart failure risk stratification and efficacy of sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes mellitus". Circulation 2019;140:1569-1577.

    CrossrefMedlineGoogle Scholar

  • 62. Nowak C., Ärnlöv J. "Kidney disease biomarkers improve heart failure risk prediction in the general population". Circ Heart Fail 2020;13:e006904.

    CrossrefMedlineGoogle Scholar

  • 63. Mehta R., Ning H., Bansal N., et al. "Ten-year risk-prediction equations for incident heart failure hospitalizations in chronic kidney disease: findings from the Chronic Renal Insufficiency Cohort Study and the Multi-Ethnic Study of Atherosclerosis". J Card Fail 2022;28:540-550.

    CrossrefMedlineGoogle Scholar

  • 64. Agarwal R., Filippatos G., Pitt B., et al. "Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis". Eur Heart J 2022;43:474-484A.

    CrossrefMedlineGoogle Scholar

  • 65. Filippatos G., Anker S.D., Agarwal R., et al. "Finerenone reduces risk of incident heart failure in patients with chronic kidney disease and type 2 diabetes: analyses from the FIGARO-DKD trial". Circulation 2021;145:437-447.

    CrossrefMedlineGoogle Scholar

  • 66. Heerspink H.J.L., Stefánsson B.V., Correa-Rotter R., et al. "Dapagliflozin in patients with chronic kidney disease". N Engl J Med 2020;383:1436-1446.

    CrossrefMedlineGoogle Scholar

  • 67. Levey A.S., Coresh J., Balk E., et al. "National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification". Ann Intern Med 2003;139:137-147.

    CrossrefMedlineGoogle Scholar

  • 68. Looker H.C., Mauer M., Saulnier P.J., et al. "Changes in albuminuria but not GFR are associated with early changes in kidney structure in type 2 diabetes". J Am Soc Nephrol 2019;30:1049-1059.

    CrossrefMedlineGoogle Scholar

  • 69. Wiviott S.D., Raz I., Bonaca M.P., et al. "Dapagliflozin and cardiovascular outcomes in type 2 diabetes". N Engl J Med 2019;380:347-357.

    CrossrefMedlineGoogle Scholar

  • 70. Kazory A. "The congestion-creatinine interplay in acute heart failure: time to move up to the next level". Am J Med 2020;133:259-260.

    CrossrefMedlineGoogle Scholar

  • 71. Jun M., Ohkuma T., Zoungas S., et al. "Changes in albuminuria and the risk of major clinical outcomes in diabetes: results from ADVANCE-ON". Diabetes Care 2018;41:163-170.

    CrossrefMedlineGoogle Scholar

  • 72. Scirica B.M., Mosenzon O., Bhatt D.L., et al. "Cardiovascular outcomes according to urinary albumin and kidney disease in patients with type 2 diabetes at high cardiovascular risk: observations from the SAVOR-TIMI 53 trial". JAMA Cardiol 2018;3:155-163.

    CrossrefMedlineGoogle Scholar

  • 73. Hillege H.L., Fidler V., Diercks G.F.H., et al. "Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population". Circulation 2002;106:1777-1782.

    CrossrefMedlineGoogle Scholar

  • 74. Matsushita K., van der Velde M., Astor B.C., et al. "Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis". Lancet 2010;375:2073-2081.

    CrossrefMedlineGoogle Scholar

  • 75. van der Velde M., Matsushita K., Coresh J., et al. "Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts". Kidney Int 2011;79:1341-1352.

    CrossrefMedlineGoogle Scholar

  • 76. Atkins R.C., Briganti E.M., Lewis J.B., et al. "Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy". Am J Kidney Dis 2005;45:281-287.

    CrossrefMedlineGoogle Scholar

  • 77. Schmieder R.E., Mann J.F.E., Schumacher H., et al. "Changes in albuminuria predict mortality and morbidity in patients with vascular disease". J Am Soc Nephrol 2011;22:1353-1364.

    CrossrefMedlineGoogle Scholar

  • 78. Heerspink H.J.L., Greene T., Tighiouart H., et al. "Change in albuminuria as a surrogate end point for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials". Lancet Diabetes Endocrinol 2019;7:128-139.

    CrossrefMedlineGoogle Scholar

  • 79. de Boer I.H., Gao X., Cleary P.A., et al. "Albuminuria changes and cardiovascular and renal outcomes in type 1 diabetes: the DCCT/EDIC study". Clin J Am Soc Nephrol 2016;11:1969-1977.

    CrossrefMedlineGoogle Scholar

  • 80. Heerspink H.J.L., Persson F., Brenner B.M., et al. "Renal outcomes with aliskiren in patients with type 2 diabetes: a prespecified secondary analysis of the ALTITUDE randomised controlled trial". Lancet Diabetes Endocrinol 2016;4:309-317.

    CrossrefMedlineGoogle Scholar

  • 81. Harrison T.G., Tam-Tham H., Hemmelgarn B.R., et al. "Change in proteinuria or albuminuria as a surrogate for cardiovascular and other major clinical outcomes: a systematic review and meta-analysis". Can J Cardiol 2019;35:77-91.

    CrossrefMedlineGoogle Scholar

  • 82. Bhatt D.L., Szarek M., Steg P.G., et al. "Sotagliflozin in patients with diabetes and recent worsening heart failure". N Engl J Med 2021;384:117-128.

    CrossrefMedlineGoogle Scholar

  • 83. Anker S.D., Butler J., Filippatos G., et al. "Empagliflozin in heart failure with a preserved ejection fraction". N Engl J Med 2021;385:1451-1461.

    CrossrefMedlineGoogle Scholar

  • 84. Teerlink J.R., Diaz R., Felker G.M., et al. "Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure". N Engl J Med 2021;384:105-116.

    CrossrefMedlineGoogle Scholar

  • 85. Jhund P.S., Solomon S.D., Docherty K.F., et al. "Efficacy of dapagliflozin on renal function and outcomes in patients with heart failure with reduced ejection fraction: results of DAPA-HF". Circulation 2021;143:298-309.

    CrossrefMedlineGoogle Scholar

  • 86. Mc Causland F.R., Lefkowitz M.P., Claggett B., et al. "Angiotensin-neprilysin inhibition and renal outcomes in heart failure with preserved ejection fraction". Circulation 2020;142:1236-1245.

    CrossrefMedlineGoogle Scholar

  • 87. Coresh J., Heerspink H.J.L., Sang Y., et al. "Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies". Lancet Diabetes Endocrinol 2019;7:115-127.

    CrossrefMedlineGoogle Scholar

  • 88. Heerspink H.J.L., Kröpelin T.F., Hoekman J., de Zeeuw D. "Drug-induced reduction in albuminuria is associated with subsequent renoprotection: a meta-analysis". J Am Soc Nephrol 2015;26:2055-2064.

    CrossrefMedlineGoogle Scholar

  • 89. Solomon S.D., McMurray J.J.V., Claggett B., et al. "Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction". N Engl J Med 2022;387:1089-1098.

    CrossrefMedlineGoogle Scholar

  • 90. Zannad F., Ferreira J.P., Pocock S.J., et al. "Cardiac and kidney benefits of empagliflozin in heart failure across the spectrum of kidney function: insights from the EMPEROR-Reduced trial". Circulation 2020;143:310-321.

    CrossrefMedlineGoogle Scholar

  • 91. Damman K., Gori M., Claggett B., et al. "Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure". J Am Coll Cardiol HF 2018;6:489-498.

    Google Scholar